Cardiovascular diseases still represent the leading cause of death in industrialized countries. Beside the development of novel and more selective pharmacological strategies in counteracting cardiovascular diseases, morbidity and mortality due to cardiovascular disorders still remain nearly unchanged. Moreover, the increased cost for supporting an enhanced consumption of drugs for preventing and combating cardiovascular diseases, represents a novel socio-economic problem of sustainability for institutional stakeholders. This Meeting aims to re-assess the most recent advances in cardiovascular pharmacology, with a special focus on clinical trials and “real world evidence” approach alongside with pharmaco-economic studies oriented to better sustainability of cardiovascular pharmacotherapy.